Cytokine Targeting in Cancer Immunotherapy

Cytokine targeting represents a pivotal strategy to modulate the immune response against cancer cells by either enhancing pro-inflammatory signals or inhibiting immunosuppressive factors. These small proteins, secreted in the tumour microenvironment, orchestrate the activation, differentiation and trafficking of immune cells. Therapeutic approaches include monoclonal antibodies that neutralise cytokines or their receptors, recombinant cytokine agonists and engineered cellular therapies. Key targets such as interleukin-6, interleukin-17 and tumour necrosis factor-α have been implicated in shaping antitumour immunity and influencing patient responses to immune checkpoint inhibitors. By fine-tuning cytokine networks, researchers aim to amplify cytotoxic T cell functions, overcome resistance mechanisms and reduce immune-related adverse events. Clinical translation has yielded promising biomarkers for patient stratification and combination regimens that integrate cytokine modulation with established immunotherapies.

Research from Nature Portfolio

Recent studies have illuminated the role of specific cytokines in enhancing combination immunotherapies. One investigation demonstrated that elevated interleukin-17 signatures in melanoma predict augmented responses to dual blockade of CTLA-4 and PD-1, driven by Th17 cell activity and neutrophil recruitment. Neutralisation of IL-17A abrogated the synergistic effects, underscoring its potential as a stratification biomarker. In parallel, foundational work on tumour necrosis factor-α revealed that blockade of TNFα improved efficacy of anti-PD-1 therapy in preclinical melanoma models by preventing checkpoint-induced T cell apoptosis and downregulating inhibitory ligands. These findings collectively advance the concept that targeted cytokine modulation can reinvigorate exhausted T cells and mitigate resistance to checkpoint inhibitors.

Cytokine Targeting in Cancer Immunotherapy publication trend

The graph below shows the total number of articles in cytokine targeting in cancer immunotherapy across all publications each year (not limited to Nature Index journals).

Technical terms

Cytokine: A small secreted protein that mediates communication between cells of the immune system, influencing inflammation and cell proliferation.

Interleukin-6 (IL-6): A pleiotropic cytokine with roles in inflammation, immune regulation and tumour progression, often targeted to enhance antitumour immunity.

T helper 17 (Th17) cells: A subset of CD4+ T lymphocytes that produce interleukin-17 and contribute to inflammatory and antitumour responses.

Tumour necrosis factor-α (TNFα): A pro-inflammatory cytokine that can induce tumour cell death but also promote chronic inflammation and immune suppression.

Programmed cell death protein 1 (PD-1): An inhibitory receptor on T cells that, when engaged, reduces cytotoxic activity and is a target of checkpoint inhibitor therapy.

Cytotoxic T lymphocyte-associated protein 4 (CTLA-4): An immune checkpoint receptor that downregulates T cell activation and is targeted by antibodies to enhance antitumour immunity.

Immune Checkpoint Inhibitor (ICI): A therapeutic antibody that blocks inhibitory receptors or ligands on immune cells to restore antitumour activity.

Tumour Microenvironment (TME): The complex milieu of cancer cells, immune cells, cytokines and extracellular matrix that influences tumour progression and response to therapy.

References

1. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nature Cancer (2023).
2. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nature Communications (2017).
3. The antitumor activity of TGFβ-specific T cells is dependent on IL-6 signaling. Cellular & Molecular Immunology (2024).
4. Immunotherapeutic IL-6R and targeting the MCT-1/IL-6/CXCL7/PD-L1 circuit prevent relapse and metastasis of triple-negative breast cancer. Theranostics (2024).
5. CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Reports Medicine (2023).